---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-374328"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2026-08-28T20:05:51+00:00"
generated_at: "2026-08-28T20:08:19.795780+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sangamo sells ST-920 Fabry gene therapy to PTC for $111M cash plus $100M milestones in Chapter 11

## Summary
- Sangamo filed Chapter 11 on June 23, 2026; PTC won auction for ST-920 assets.
- Deal: $111M cash at closing plus up to $100M milestones; $80M on FDA accelerated approval, $20M on full approval.
- Bankruptcy Court hearing to approve sale scheduled for September 10, 2026; closing by October 15, 2026.
- ST-920 is AAV gene therapy for Fabry disease; PTC assumes specified liabilities.
- Stock delisted from Nasdaq May 5, 2026; now trades OTC as SGMOQ.

## SEC filing metadata
- accession: 0001193125-26-374328
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2026-08-28T20:05:51+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 1.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000119312526374328/0001193125-26-374328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000119312526374328/d116527d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-374328
- JSON: https://secwatch.observer/filing/0001193125-26-374328.json
- Plain text: https://secwatch.observer/filing/0001193125-26-374328.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.